Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Investor Securities Class Action Lawsuit 02/14/2017

If you purchased a significant amount of shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) between February 10, 2015 and December 27, 2016, and / or if you purchased any NASDAQ:ANTH shares prior to February 2015 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: April 17, 2017. NASDAQ:ANTH investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Anthera Pharmaceuticals
Case Name: 
Anthera Pharmaceuticals Shareholder Class Action Lawsuit 02/14/2017
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: ANTH
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
02/14/2017
Class Period Begin: 
02/10/2015
Class Period End: 
12/27/2016
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 
04/17/2017
Summary: 

February 14, 2017 (Shareholders Foundation) - An investor in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Anthera Pharmaceuticals Inc in connection with certain allegedly false and misleading statements made between February 10, 2015 and December 27, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) common shares between February 10, 2015 and December 27, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 10, 2015 and December 27, 2016, Anthera Pharmaceuticals Inc made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that patients were not improving in the CHABLIS-SC1 clinical trial, and that there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

Hayward, CA based Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune disease. Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) reached in 2015 as high as $10.91 per share.

On November 10, 2016, Anthera Pharmaceuticals Inc announced that “the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.”

On December 27, 2016, Anthera Pharmaceuticals Inc announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase.

Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) declined to as low as $0.64 per share on December 30, 2016.